For immediate release |
22 May 2009 |
ALLIANCE PHARMA PLC
('the Company')
Major Interest in Shares
Alliance Pharma plc (AIM: APH), the speciality pharmaceutical company, was informed on 22 May 2009
that Nigel Wray purchased, on 21 May 2009, a further 1,800,000 ordinary shares of 1p each in the Company.
Mr Wray's resultant shareholding is 16,669,995 ordinary shares, equivalent to 10.29% of the Company's
issued share capital.
Mr Wray's ordinary shares are held as follows:
Nominee |
Number of ordinary shares |
Pershing Keen Nominees Limited Smith & Williamson Nominees Limited RBC Dexia London Account 22607 |
4,799,407 50,000 11,820,588 |
For further information:
Alliance Pharma plc
|
+ 44 (0) 1249 466966
|
John Dawson, Chief Executive
|
|
Richard Wright, Finance Director
|
|
|
|
|
|
Buchanan Communications
|
+ 44 (0) 20 7466 5000
|
Mark Court / Rebecca Skye Dietrich / Stasa Filiplic
|
|
|
|
Numis Securities Limited
|
+ 44 (0) 20 7260 1000
|
Nominated Adviser: Michael Meade / Brent Nabbs
|
|
Corporate Broking: David Poutney
|
|
Notes to editors
About Alliance Pharma
Alliance Pharma, founded in 1998, is an AIM listed speciality pharmaceutical company based in Chippenham, Wiltshire, UK. The company has a strong track record of acquiring the rights to established niche brands and owns, or licenses, the rights to 35 branded pharmaceutical products and continues to explore opportunities to expand the range.
Alliance Pharma's products are prescribed in the treatment of a wide range of conditions and include brands used in the treatment of dermatological conditions, in childbirth, in the prevention of heart disease, in Parkinson's disease, in nutrition and in nasal infections. Alliance Pharma's sales are mainly prescription driven. Its products are distributed to hospitals directly and to pharmaceutical wholesalers, which service both hospital and retail pharmacies with their prescription requirements.
Alliance Pharma joined the AIM market of the London Stock Exchange in December 2003 and trades under the symbol APH.